Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents
  • ErbB Receptors
  • Neoplasms

abstract

  • The recommended dose for disease-directed studies of OSI-774 administered orally on a daily, continuous, uninterrupted schedule is 150 mg/d. OSI-774 was well tolerated, and several patients with epidermoid malignancies demonstrated either antitumor activity or relatively long periods of stable disease. The precise contribution of OSI-774 to these effects is not known.

publication date

  • July 2001

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1200/JCO.2001.19.13.3267

PubMed ID

  • 11432895

Additional Document Info

start page

  • 3267

end page

  • 79

volume

  • 19

number

  • 13